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ABSTRACT
The goal of CERVIS is to increase screening for cervical cancer through the development of a
low-cost, minimally invasive screening procedure for women in low-resource settings that
requires minimal healthcare expertise. There currently exist two primary screening procedures:
the Pap smear, primarily used in developed countries, and visual inspection with acetic acid
(VIA), primarily used in low and middle-income countries (LMICs). Both of these procedures
require a high degree of healthcare training in order to administer and interpret, and are highly
invasive, requiring direct interaction with the cervix. Our alternative procedure utilizes a
particular bacteria, Fusobacterium nucleatum, within the cervicovaginal microbiome that has
been associated with cervical cancer pathology. Our screening procedure seeks to identify the
need for further diagnostic testing based on a vaginal swab representative of fusobacteria
colonization of the vagina. Two modalities, growth media containing colorimetric indicators and
a qPCR-based assay, are used to qualitatively and quantitatively measure the presence of this
bacteria. This collection method is less invasive and does not require healthcare expertise,
therefore allowing for self-administration. Outcomes of testing are measured by determining the
feasibility of the prototype regarding sensitivity and parameters of bacterial growth, including
time for incubation, the temperature of incubation, and aerobic exposure time. Further testing
will include quantifying fusobacteria in a cervical cancer patient sample and establishing exact
temperature ranges of incubation and incubation time.
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CHAPTER 1: INTRODUCTION

1.1 Background
Globally, cervical cancer ranks fourth in incidence and in cancer-related mortality among
women, with the majority of cases occurring in low and middle-income countries (LMICs)
(WHO, 2019). These high incidence and mortality rates are due to delayed diagnosis, which
means that cervical cancer often goes undetected for several years. The WHO states that 90% of
those cervical cancer-related deaths occur in LMICs, many of which could be prevented by early
screening and diagnosis (WHO, 2019). Human Papillomavirus (HPV) is the most common risk
factor for cervical cancer, and proper implementation of an HPV vaccine helps to prevent this
disease (Liu & Richardson, 1987). However, while this vaccine is widely used in developed
countries, it is not implemented on a national level in many LMICs, and even if programs exist
these are not effective (Nakisige, 2017). Vaccines are in the process of being implemented but
would be ideally administered to girls in their pre-teenage years, and as such the effects of such a
vaccine would take many years to be able to see results. Furthermore, to decrease the incidence
of the disease, it is still necessary to address prevention factors while also pursuing cervical
cancer screening, diagnostic and treatment measures.

Additional prevention methods that enable detection of precancerous changes before progression
to invasive disease are also being developed to help reduce the prevalence of cervical cancer
cases (Finocchario-Kessler, 2016). Screening is a very common prevention method, but in
LMICs, the screening rates remain very low (Gyawali, 2015; Runge, 2019). This is often because
there are shortages in the necessary supplies to perform these screening tests and a lack of trained
healthcare personnel to administer these tests (PATH, 2019). Cervical cancer education is an
additional preventative measure to help inform women of the risks and proper safety practices
surrounding unsafe sex, but many LMICs currently lack this sort of education.
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1.2 Significance of Project
Although cervical cancer is the 4th most common cancer in women worldwide, there are
currently no low-cost, minimally-invasive screening tests available. Due to the prevalence of
cervical cancer, the HPV vaccine is not simply a replacement for screening. Implementing the
HPV vaccine is a proactive prevention measure, whereas screening is reactionary to the
development of cervical cancer, preventing its progression to later stages. Current cervical cancer
screening procedures identify DNA and protein biomarkers from cervical samples but are
expensive, difficult to administer, and often invasive. These factors limit test feasibility in
low-resource areas, creating a need for new screening technologies.

Team CERVIS aims to increase screening in Uganda by developing a low-cost,
minimally-invasive screening test that can be self-administered and requires minimal healthcare
expertise. Last year’s test created a prototype for this screening test, and this year our focus is on
determining the feasibility of that prototype by determining its sensitivity and optimal
implementation parameters.

1.3 Proposed Goals
Team CERVIS, a group of undergraduate students from Santa Clara University departments of
Bioengineering and Public Health, aims to build on a promising prototype designed to detect the
presence of fusobacteria on a vaginal swab. Fusobacteria is an anaerobic bacteria found in the
cervical and vaginal microbiomes that is found in increased concentrations in cervical cancer
(Audirae Chalifour et al., 2016). The prototype contains media that will change color due to a
reaction with fusobacteria present on a vaginal swab. While last year’s team successfully proved
that the media was specific to fusobacteria, it is still unclear whether the prototype is sensitive
enough to detect the amount of fusobacteria present in vaginal samples of patients with cervical
cancer. Furthermore, this year, team CERVIS explored the feasibility of implementing this
prototype, including testing the sensitivity of the media along with determining optimal
implementation parameters.
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CHAPTER 2: PROJECT OVERVIEW

2.1 Target Population
The development of the prototype requires a targeted population to establish a deployment
strategy and to measure the current impacts of cervical cancer and its preventative strategies. Our
chosen target population is women in Uganda, where one of the highest incidences of cervical
cancer in the world is observed, as well as a low screening rate (Black, 2019). Uganda lacks
many primary and secondary preventative methods to help reduce cases of cervical cancer.
Uganda is a Sub-Saharan country in Eastern Africa, with a population of nearly 32 million. Each
year, about 40.5 in 100,000 Ugandan women die of cervical cancer compared to 6.8, the global
average (Black, 2019). Cultural reticence to seek routine invasive pelvic examinations also
prevents women from seeking treatment until the disease has progressed to severe, symptomatic
stages (WHO Training Guide 2015). Up to half of women diagnosed with late-stage cervical
cancer die within 3 years of diagnosis (Wabinga, et al., 2000), and up to 80 percent of those
women die within 5 years (Gondos, et al., 2005). Increased, minimally invasive screening could
prevent such deaths from occurring.

Presently, despite Uganda’s nationally-implemented HPV vaccine program, efforts by the
Ministry of Health have been uncoordinated and had limited success (Nakisige et.al., 2017).
Furthermore, in 2016, only 4.8% of women have been screened (Campos et.al., 2017).
Successful implementation of an HPV vaccine program would greatly decrease the incidence of
cervical cancer, but screening and diagnostic technology are still required in order to effectively
combat mortality rates from this disease. Finally, our team currently has connections to a
non-governmental organization (NGO), Rose Academies, and several clinics there. Therefore, it
makes it an ideal location to develop a deeper understanding of our target population’s needs,
and could also establish a relationship for future product deployment.
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2.1.1 Parameters for Deployment
There are several parameters that need to be considered prior to deployment of the prototype, but
a select few were determined to be the most pressing to assess feasibility given the limits of
conditions in Uganda. Currently, women in rural areas travel to receive healthcare or have
outreach teams visit them to provide healthcare services (Jeronimo et al., 2014). We wanted to
establish a baseline incubation time for the color change to evaluate the feasibility of our
prototype in the field. Incubation temperature of the fusobacteria is another major factor to
properly produce an indicative dark gray color. Many areas may not have access to an incubator
to maintain the standard temperature of incubation for fusobacteria, so this parameter is explored
throughout our experiments to determine whether or not an incubator is a necessary element for
proper prototype functionality. Finally, due to the anaerobic nature of our target bacteria, we
have considered aerobic exposure as an important parameter to analyze for feasibility.
Determining how long a swab can be exposed to air prior to insertion into the media will help to
develop a proper protocol for healthcare clinicians administering this test. Cervical cancer is a
malignant and proliferative disease in countries like Uganda, but Team CERVIS aims to reduce
its severe incidence and mortality that women suffer.

2.2 Review of the Field: Current Detection Methods
The key to preventing and addressing cervical cancer development is preventative medicine and
routine screenings. Current guidelines for women recommend annual cervical cancer screening
for HPV-positive women, and every 3 years for all others, but in actuality is irregular and often
determined by resource availability (CDC, 2018). Pap smear is most common in developed
nations while Visual Inspection with Acetic acid (VIA) is used more often in poorly resourced
areas (Gaffikin, 2002).

2.2.1 Pap Smear
Pap smears and colposcopies are the most common cervical cancer screening methods to
accurately detect cellular processes of both precancerous and cancerous samples within a swab
sample of the cervix (Markovic, 1998). Pap smear analysis requires a high degree of technical
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and clinical knowledge to identify and swab the cervix correctly to interpret sample results for
appropriate diagnosis. Not only is the equipment to analyze the sample expensive and laboratory
access required for proper and effective analysis, but these procedures have a high number of
false positives. Moreover, individual patients have indicated that Pap smears and colposcopy are
invasive, painful, and costly, requiring regular screening every 2-3 years (Markovic, 1998).

2.2.2 Visual Inspection with Acetic Acid (VIA)
Visual Inspection with Acetic Acid (VIA) of the cervix is an inexpensive screening method used
primarily in poorly resourced areas (Gaffikin, 2002). This screening test is performed by trained
health workers and nurses in women’s health clinics as well as mobile screening camps in
low-income areas. The test is invasive and can cause some discomfort similar to the Pap smear
method because of the insertion of a self-retaining vaginal speculum. After insertion, acetic acid
is applied to the cervix and observed for a reaction between the suspected lesion and the acetic
acid indicated by a color change (Gaffikin, 2002). Similar to limitations of other screening
procedures, VIA requires a high degree of technical knowledge to properly administer the
screening, must be done in a clinical environment, and is highly invasive. If the test is not
administered properly, bubbles may form, resulting in false positives (Mandelblatt, 2002).

The limitations of these current technologies highlight the need for a cost-effective medical
screening procedure that enables women in low resource settings, without access to advanced
medical care, to accurately test for cervical cancer. Furthermore, the results of the screening
should be easily understood by individuals with little to no technical medical background.

2.3 Vaginal Microbiome
One of the newest avenues of cancer detection research involves microbiota, which are the
microbial communities present in certain areas of the body. These include the gastrointestinal
tract, oral cavity, and the cervicovaginal regions. This class of organisms was chosen as a target
for our prototype because current literature indicates that dysbiosis, a microbial imbalance, has
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been linked to many diseased states, from irritable bowel syndrome to many types of cancers,
including cervical cancer (Kriss et. al., 2018).
There are many factors that influence the composition of the vaginal microbiome. These can
include hygiene, lifestyle factors (i.e. sexual health, contraceptives, etc.), pregnancy, and
menopause. The composition can change several times throughout a single individual’s lifetime.
The bacteria present in the vaginal microbiome can be classified in one of five ways, referred to
as Community State Types (CSTs). Each females’ vagina can be classified as CST I-V, with
dominant bacteria in each category. The most common CSTs are III and IV, and an individual
can transition from CST III to CST IV during their lifetime, and transitions between any two
community state types are common (Gupta, et. al, 2019).
Of particular interest to our team is the prevalence of vaginal dysbiosis in Sub-Saharan Africa
(van de Wijgert and Jespers, 2017). A definitive causal link has been established between vaginal
dysbiosis and cervical cancer from oncogenic HPV acquisition to cervicovaginal precancerous
development, meaning that detection by this manner has the capability of detecting early-stage
cervical cancer (Brusselaers, 2019)

2.3.1 Fusobacteria
Fusobacteria strains have been detected in pathogenic dysbiosis of microbiomes such as the
colon, oral mucosa, and gut (Han, 2015). Recent work has also correlated its presence to cervical
cancer pathology. Vaginal dysbiosis is often observed in correlation with a change in the ratio of
healthy to pathological microorganisms, including an increase in the amount of fusobacteria.
This dysbiosis, caused by infection or other pathology, can increase a patient’s risk to develop
more serious conditions such as cervical cancer (Gupta et al, 2019).
Studies have shown that Fusobacterium nucleatum i s upregulated in correlation with cervical
cancer, finding that it constitutes approximately 17% of the cervical microbiome in this disease
state (Audirac-Chalifour et al., 2016). F. nucleatum is an obligate anaerobe, meaning that it can
only grow in conditions where oxygen is absent. This is the bacteria that we are targeting with
our research and experiments because it provides the most conclusive link to cervical cancer in
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patients diagnosed with the disease, and is not present in high levels in the healthy microbiome.

2.4 Quantification Methods
Sensitivity testing is required in order to determine the accuracy of a screening procedure. This
testing measures how often a test correctly generates a positive result when the targeted
condition is present. This is known as the true positive rate (King and Mody, 2010). Producing a
true positive result is essential for an accurate screening procedure.

The National Institute of Health (NIH) launched the human microbiome project in 2008 to better
understand microbial microenvironments in specific areas of the human body and how they
contribute to human health and disease (Gevers, 2012). The vaginal microbiome was explored to
gain insight into the baseline state of a healthy vaginal microbiome. Some studies also indicated
that in women affected by cervical cancer, the composition of fusobacteria in the vaginal
microbiome is 17% (Audirac-Chalifour et al., 2016). The composition of cervical and vaginal
flora specimens has been proven to be comparable, therefore the vaginal microbiome can be
representative of the cervical microbiome (Smith et. al., 2014).

2.4.1 Colony Forming Units (CFU)
When performing a quantitative test, there are several available methods for establishing a
baseline. The selection of the proper method depends on the degree of precision desired. One of
the easiest and most common quantification methods is counting colony-forming units (CFUs).
This method is regarded as the gold standard for determining bacterial cell number (Hazan et al,
2012). Utilizing this method is beneficial because only viable bacterial colonies are counted,
excluding any dead bacteria and debris (Hazan et. al., 2012). The most significant disadvantage
of this method is that clumps of bacteria cells can be miscounted as single colonies. While no
specialized equipment is required for counting CFUs, there are several limitations to this method,
including an extended incubation time of several days in order to obtain observable colonies.
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2.4.2 Microscopy
Compound microscopy is another method commonly utilized in bacterial quantification.
Hemocytometers are used in conjunction with the microscope in order to determine absolute cell
count. Using this method can be difficult because it requires the ability to differentiate between
bacterial cells and debris, as well as being able to clearly identify clumps of bacteria (Hazan et.
al., 2012). This method requires a specialized microscope and a hemocytometer plate, but results
can be obtained in a shorter amount of time than CFU counting because cells can be counted
without incubating first.

2.4.3 qPCR
Quantitative Polymerase Chain Reaction (qPCR) or Real-Time PCR is a method commonly used
to quantify the abundance of particular microbial DNA. Analysis via qPCR combines traditional
end-point detection PCR with detection by fluorescent expression technologies to record
amplification in “real time” (Smith et. al., 2009). This method also provides wide sequence
coverage, as it can specifically target particular taxonomic or functional markers from bacterial
domain down to specific bacterial strains. The results from this method can be obtained in
approximately 1.5 hours, but post-analysis can be difficult and time-consuming, particularly in
developing an absolute standard curve. The standard curve development itself requires initial
quantification by one of the aforementioned methods for qPCR verification.

The table below summarizes the benefits and limitations of each of the accessible microbial
quantification methods.
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Table 1. Methods of Bacterial Quantification
Quantification

Benefits

Limitations

Method
Colony-forming
units (CFUs)

● Easy to conduct
● Counts only live cells
● Range of detection unlimited

● Time-consuming
● Susceptible to
contamination

Compound
Microscopy

● Range of detection unlimited
● Quick results

● Relies on the ability of
viewer to count bacterial
colonies, large potential for
human error

● Counts bacterial DNA from live,
dead or injured cells
● Can specifically target a particular
bacterial strain
● Quantification of up to 96 samples
at once
● Fairly quick results (hours)

● Tedious experimental
procedure may lead to
errors
● Post-analysis with standard
curves is complicated

qPCR

2.5 Team and Project Management
The project team is composed of three Bioengineering (BIOE) majors in conjunction with five
Santa Clara University (SCU) faculty members, two Public Health science majors from the
Engineering World Health (EWH) partnership, and Hiram Lozano from Anaerobe Systems. The
faculty advisors are Dr. Prashanth Asuri, Dr. Michele Parker, Dr. Craig Stephens, Dr. Emily
Park, and Dr. Elizabeth Dahlhoff. Dr. Prashanth Asuri has served as a Bioengineering advisor.
Dr. Michele Parker has served as a Public Health advisor and a mentor to the Engineering World
Health sector of the project. Dr. Craig Stephens has served as an expert in microbiology and
advised the students on both microbiological techniques and characteristics of bacteria. He also
provided the students with lab space and supplies. Dr. Park has served as an advisor for
designing qPCR experiments. Dr. Dahlhoff provided lab space, materials, and expertise in
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running a qPCR experiment. Lauren Cherrey and William Nelson acted as public health student
partners for the project, advising the BIOE team about relevant ethical and cultural issues.
This project originally stemmed from the work of a 2017-18 senior design group and subsequent
iteration during the 2018-19 school year. Within the BIOE student team, all experimental design,
presentations, intra-team communication, and lab work were completed together. In addition to
baseline roles, individual team members had responsibilities of their own. Juliana Trujillo
managed supply orders and was the point of contact with the School of Engineering, Lauren
Serfas organized meetings and was the primary point of contact with advisors, and Kira Palazzo
was the lead point of contact with Anaerobe Systems, managing updates and supply shipments
from the company to SCU.

2.5.1 Budget
The funds provided for experimentation and development of our senior design project were
requested from the Santa Clara University Undergraduate Programs. The awarded funding is
summarized in Table A found in Appendix A. Additionally, a detailed outline of the
expenditures of the project totaling $1,431.32 can be found in Table B in Appendix A.

2.5.2 Timeline
Reference Appendix A, Table C for an overview of completed action items for the CERVIS
project for the 2019-20 school year.
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CHAPTER 3: CERVIS PROTOTYPE PARAMETERS
We chose three initial parameters to test conditions for feasibility: incubation time, incubation
temperature, and aerobic exposure prior to insertion into the CERVIS media. We chose these
parameters as the most pressing questions to assess feasibility given the limits of conditions in
Uganda.

3.1 Incubation Time
In rural areas of Uganda, access to clinical settings may be limited. For this reason, it is
important to minimize clinical wait times for the CERVIS screening procedure. Once the
screening has been performed, results are not immediately available because of the necessity to
culture the CERVIS tubes in an incubator. The purpose of the incubation time parameter test is
to determine the minimum amount of time necessary for a true positive to be produced. This
would be necessary for the deployment of the procedure in Uganda because it would allow for
identifiable wait times, minimizing patient anxiety, and increasing ease of processing for
healthcare personnel.

3.1.1 Methods
In preparation to grow fusobacteria, the anaerobic chamber was turned on and allowed to purge
for 24 hours to remove oxygen and establish an anaerobic environment.

Entering the Anaerobic Chamber
Fusobacteria plates, which had been cultured for 96 hours, were removed and photographed.
After the plates had been properly documented, viable colonies were removed from plates using
sterile inoculating loops and placed into a 9 mL dilution blank. The dilution blank was then
resealed and vortexed at speed 7 for ten seconds. Once this was completed, 1 mL of the solution
was withdrawn from the tube and added to another 9 mL dilution tube to create a tenfold
dilution. Once this was completed, the dilution tube was sealed and then vortexed on 7 speed for
10 seconds to distribute the bacteria through the solution. Following the vortex, 20 µL was added
to a sterile swab of the bacteria-containing solution; 20 µL was the amount determined to be the
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maximum volume retained on the chosen swabs. This swab was then inserted into the media and
sealed. The CERVIS tube was then placed into the passbox, sealed from the inside, and the team
member exited the chamber.

Outside of the Chamber
Once removed from the chamber, the CERVIS tube was incubated at 37 ℃ and documented at 0,
24, 48, and 72 hours.

3.1.2 Preliminary Results
According to qualitative analysis, a color change did not occur in the media at all until 48 hours,
with a more substantial color change occurring at 72 hours. However, these results do not
provide conclusive evidence for the exact point at which a true positive can be observed, so
further tests would be necessary to confirm this.

Incubation Time
0 hrs

24 hrs

48 hrs

72 hrs

Figure 1: Incubation Time Parameter Results
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3.2 Incubation Temperature
In rural villages in Uganda, access to an incubator may be severely limited, so we wanted to
explore alternative incubation temperatures that could result in a true positive result without the
use of a traditional incubator.

3.2.1 Methods
Within the Anaerobic Chamber
See section 3.1.1 for details on placing fusobacteria into CERVIS media tubes.

Outside of the Anaerobic Chamber
The four CERVIS tubes designated for temperature parameter testing were placed in various
temperatures in order to determine if bacterial growth was possible. One tube was designated to
be at room temperature, 25 ℃, one was placed in a 37 ℃ incubator, one in a 30 ℃ incubator,
and one in an outdoor area that would experience temperature fluctuations throughout the day.
The tube placed outside was in a shaded area so that direct sunlight would not be a confounding
variable. Each tube was documented after 72 and 98 hours, though the outdoor tube was only
documented at 72 hours.
3.2.2 Preliminary Results
Without access to an incubator, it is likely that access to this procedure would be severely
limited. According to preliminary testing, bacterial growth occurs only at 37 ℃.
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Temperature
Varying

25 ℃

37 ℃

30 ℃

72 hours

98 hours

Not pictured

Figure 2: Temperature Parameter Testing Results (72 and 98 hours)
3.3 Aerobic Exposure
During sample collection, it is likely that the vaginal swab would be exposed to air for at least
several seconds to several minutes following collection by the patient. For this reason, tests were
conducted to determine the maximum time for aerobic exposure that would allow the procedure
to maintain viability. That is, the test was necessary to determine if exposure to air would still
allow for a true positive result of the CERVIS procedure. A true positive can be obtained only if
fusobacteria growth occurs, and this test would confirm the degree to which exposure of this
anaerobic bacteria to air would inhibit growth.
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3.3.1 Methods
Within the Anaerobic Chamber
Once it had been confirmed that the chamber was anaerobic, the team opened the incubator and
took pictures of each plate. Fusobacteria that was designated for aerobic exposure testing was
cultured. The plates were assessed for viable colony growth and set aside. Approximately 30
viable fusobacteria colonies from the plates were ‘picked’ via a sterile 1 μL inoculating loop and
placed into a tube containing 5 mL of dilution solution The inoculating loop was shaken
vigorously to release the colonies into the dilution solution and the tube was sealed with the cap.
The tube was then vortexed at speed setting seven for ten seconds to ensure even distribution of
fusobacteria throughout the solution.

Next, each swab was prepared to be inserted into the media. To do this, we vortexed the tube
containing the bacteria for ten seconds, then removed the cap and removed 20 μL of the
bacteria-containing solution. This was pipetted onto a swab, turning the swab as the solution was
released to coat it in solution. Following this, the swab was then plunged into the CERVIS media
and sealed with the cap.

The twelve swabs were designated for aerobic exposure testing. The procedure of vortexing the
bacteria-containing solution and adding it to the swab was repeated for each swab, after which
the swab was placed in the tube rack with the tip of the swab facing upwards. Prior to exiting the
chamber the tube rack with swabs was placed in the passbox and was sealed from the inside.

Outside of the Anaerobic Chamber
Before opening the passbox, we collected a timer and twelve new CERVIS media tubes, along
with a tube rack to stand those in. We labeled duplicate tubes for six aerobic exposure times--15,
30, 45, 60, 120, and 300 seconds--for a total of twelve tubes. Next, while one person was ready
to start a timer, the other got ready to open the passbox. When the passbox was opened, the timer
was started and watched until it was time to insert the swab into the media. Just before a time
point was reached, both team members opened the corresponding CERVIS media tubes, selected
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the swabs without touching the tip, carefully pushed the swabs into the media tip down, and
resealed the tubes. This process was repeated for each time point listed above. Once all tubes
contained swabs, they were placed into the 37 ℃ incubator and checked at 72 and 98 hours,
capturing images each time.

3.3.2 Preliminary Results
After 72 hours, little to no distinct growth had been observed in all of the tubes. After 98 hours,
growth was observed in all time points except for 300 seconds, but there were large
inconsistencies between duplicates at 30, 60, and 120 seconds (see Figure 3). These
inconsistencies could be explained by the variability common in bacterial suspensions such as
the one used for parameter testing. There is a possibility that the tubes that showed no growth
had not received any or received very little fusobacteria in 20 µL of the bacterial suspension that
was pipetted onto the swab.

Exposure Time
15 sec

30 sec

45 sec

60 sec

Figure 3: Aerobic Exposure Parameter Testing (98 hours)

120 sec

300 sec
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CHAPTER 4: DETERMINING SENSITIVITY OF THE CERVIS MEDIA
The overall goal of team CERVIS this year was to determine the feasibility of last year’s
prototype. In order to do that, one of the subgoals was to assess the sensitivity of the CERVIS
media to ensure it could detect the amount of fusobacteria expected in the vaginal microbiome of
a woman with cervical cancer.

4.1 Objectives
As previously mentioned, 17% of the vaginal microbiome is composed of fusobacteria. Based on
our assumptions that a vaginal swab is representative of the vaginal microbiome for the
sensitivity testing, we can conclude that approximately 17% of a vaginal swab is composed of
fusobacteria for women with cervical cancer. Knowing the approximate amount of fusobacteria
that would likely be in the vaginal swab of a woman with cervical cancer allows for a target
percentage of how sensitive the CERVIS media needs to be in order for team CERVIS to
consider last year’s prototype feasible.

It is necessary to generate a percentage that corresponds to the sensitivity of the CERVIS media
to compare to our target percentage of 17%. This percentage can be calculated by dividing the
amount of fusobacteria necessary to initiate a color change in the CERVIS media by the total
bacteria present in a vaginal swab. It has been found that total bacteria in a microbiome does not
change depending on disease states, so the number of total bacteria that is found in the vaginal
microbiome of a woman with or without cervical cancer should be approximately equal (Vickery
and Ramakrishnan, 2017).

Therefore, to evaluate the sensitivity of the CERVIS media, we had to determine:
1) How much initial fusobacteria is necessary to add to the CERVIS media for a color
change to occur (Section 4.5.1)
2) How much total bacteria is present on a vaginal swab (Section 4.5.2)

26
4.2 General qPCR Procedure
In order to quantify the amounts of fusobacteria and total bacteria present in the sample, we used
quantitative Polymerase Chain Reaction, or qPCR (see description of this quantitative method in
Section 2.4.3). The following section describes the general procedure for preparing and
performing qPCR, which are preliminary steps necessary before running our desired
experiments.

The qPCR procedure can be broken down into three primary steps:
1) Preparing dilutions of the bacterial DNA
2) Creating the Universal and Fusobacteria Master Mix and NPC
3) Combining the DNA dilutions and Master Mix on a qPCR plate
Further details can be found in Appendix B, Section 1.
4.2.1 Preparing Fusobacteria and Primers for qPCR
Primers are one of most, if not the most important, critical component of any PCR because they
control the specificity and sensitivity of the analysis (Bustin, 2017). We needed to find
“universal” primers for eubacteria, all bacteria. The universal primers used in our experiments
were taken from a study that had previously sequenced the vaginal microbiome (Mao et al.,
2012). We found species-specific primers for Fusobacterium nucleatum as it was the species
associated with cervical cancer pathology (Castellarin, et.al. 2012). The sequences of these
primers are located in Table G in Appendix A.
Preparation of our experiments entailed growing fusobacteria in an anaerobic hood and isolating
DNA for the qPCR procedure. In addition, primers had to be prepared from a lyophilized state
prior to qPCR testing. The detailed methods used to perform this are described in Appendix B,
Section 2.
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4.3 Testing Primers
Before we could begin quantifying fusobacteria in the CERVIS media or total bacteria on a
vaginal swab, we first had to ensure our qPCR procedure was working appropriately and our
reaction components were performing as expected. We began by verifying that our Universal and
Fusobacteria primers were working properly. To test the universal primers, we first ran a qPCR
experiment with Fusobacteria and E. coli. We expected both of these bacterias to produce
amplification if they were indeed universal and our procedure was appropriate. We also ran a
qPCR experiment using Fusobacteria and E. coli with the Fusobacterium nucleatum primers. In
this situation, we expected the fusobacteria to produce amplification while the E. coli would not.
4.3.1 Methods
In testing the primers, we followed General qPCR Procedure as described in Appendix B,
Section 1. We performed two ten-fold dilutions of the E. coli DNA (147 μg/mL) and fusobacteria
DNA (2.58μg/mL) and used the 101 and 103 dilutions when pipetting them onto the qPCR
plates. In preparing our Fusobacteria and UMM we calculated for 12 reactions (10 necessary + 2
additional). See Table H and Figure A in Appendix A for the total volumes and qPCR plate
setup.
4.3.2 Results

Figure 4: Amplification Plot for Testing Primers
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The amplification for both the fusobacteria and universal primers is shown in Figure 4. The
x-axis is the cycle number of the qPCR machine, and the y-axis is the change in the amount of
DNA. The lower the cycle number, the greater the amount of DNA initially present in the
sample. In order for there to be considered amplification, the curve must rise above the threshold
level, determined by the horizontal green and orange lines. The point where those two lines cross
is called the Cycle Threshold (or CT value). In the lines within area A, we see that there is clearly
amplification for both the universal and F. nucleatum primers. However, in area B, they are high
CT values
(signifying very low initial amounts of DNA) so the results are inconclusive as to

whether there was sufficient amplification or not.

The following figure (Figure 5) shows amplification in another way that is easier to assess
whether the primers were performing as expected.

Figure 5: Amplification Results for Testing Primers
The box in blue shows the controls for the experiment (water instead of any DNA and NPC
instead of the UMM or FMM). There should be no amplification for these eight reaction wells
(all purple circles). The red circles signify amplification, therefore we recognize that our controls
were not working as expected. However, looking at the amplification plot, those curves fall in
Area B, so the data was on the borderline of being considered “amplified” or not. We recognized
this inconsistency, but since these were preliminary experiments, we continued to move forward
recognizing that this data was likely due to contamination from our inexperience of running these
experiments.
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Returning to Figure 5, the top row is bacteria with the UMM (with the Universal primers), and
the bottom row is with the FMM (with F. nucleatum primers). As mentioned previously, we
expected there to be amplification with both the E.coli and F. nucleatum (which we see with the
red circles) with the UMM (the top row), but there was only amplification with F. nucleatum
with FMM (the bottom row). With the E. coli and FMM, we got results that were inconsistent
with our hypothesis, as it showed some amplification with one of E. coli concentrations. Once
again, because we saw that the FMM was amplifying F. nucleatum (which we were more
focused on), we took note of this inconsistency and continued to proceed forward with the rest of
the qPCR experiments.
4.4 Generating Absolute Standard Curves
Once we felt comfortable with the qPCR procedure and had ensured that our Universal primers
were amplifying different types of bacteria (E. coli and F. nucleatum) and our fusobacteria
primers were amplifying F. nucleatum, we then proceeded with the next step of our preliminary
sensitivity testing which was generating universal and fusobacteria absolute standard curves.
An absolute standard curve is generated from a known amount of DNA, so it can be used as a
reference for determining an unknown amount of DNA in a sample. This was important so that
we could determine the unknown amounts of initial fusobacteria in the CERVIS media and total
bacteria that were present in a vaginal swab.

We determined our known amount of fusobacteria present in our initial dilution using
microscopy (See Appendix B, Section 3). We then used the amount of fusobacteria DNA from
our microscopy results and entered them into the standard curve technology programmed into the
qPCR machine. This automatically created our Fusobacteria absolute standard curve and
universal absolute standard curve.

4.4.1 Methods
After determining through microscopy how much fusobacteria in our initial dilution, we then
followed the “General qPCR Procedure” as described in Appendix B, Section 1. We performed
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five, ten-fold dilutions of fusobacteria DNA (6.08 μg/ml) and used all five dilutions when
pipetting them onto the qPCR plate. In preparing our Fusobacteria and Universal master mix we
calculated for 13 reactions (11 necessary + 2 additional). The total volumes and qPCR can be
found in Table J and Figure B in Appendix A.
4.4.2 Results

Figure 6: Standard Curves

The fusobacteria standard curve (orange) and universal standard curve (purple) are shown in
Figure 6. The amount of bacteria is shown on the x-axis, and a measure of amplification (CT
value) is shown on the y-axis (see Results section for Testing primers for a more detailed
explanation of CT value). In order for an absolute standard curve to be considered precise enough
for determining unknown DNA amounts, the r2 value has to be greater than or equal to 0.999.
Therefore, while our fusobacteria standard curve (r2 = 1.000) would be precise enough, our
universal standard curve (r2 = 0.925) would not. Unfortunately, we were in the middle of
repeating this experiment to increase our r2 value when Santa Clara University closed all labs, so
we did not get to generate standard curves that could be used for the rest of the sensitivity
testing.
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4.5 Sensitivity Testing Experiments
Once appropriate standard curves were created, we could then return to the two primary
quantities we needed to determine in order to assess whether the CERVIS media was sensitive
enough for women with cervical cancer:
1) How much initial fusobacteria is necessary to add to the CERVIS media for a color
change to occur?
2) How much total bacteria is present on a vaginal swab of a healthy woman?
4.5.1 Determining Initial Quantity of Fusobacteria Required for Color Change
In order to determine how much initial fusobacteria was necessary for a color change to occur in
the CERVIS media, we first had to assess where a dramatic color change was occurring.
Therefore, fusobacteria was grown in an anaerobic chamber for 96 hours. Approximately 50
colonies were then placed into a dilution blank containing 9 mL of dilution solution and vortexed
well. 1 mL of this bacteria suspension was then added to a tube containing 9 mL of dilution
solution (1:10 dilution). Five 1:100 dilutions were then made by taking 100 μL of the bacteria
suspension from the previous dilution and adding it to a new tube containing 9.9 mL of dilution
solution. The contents were then vortexed well before creating the next dilution. Furthermore, in
total there were the following dilutions: the initial dilution, 1:101, 1:103, 1:105, 1:107, and 1:109.

From the dilutions following the initial one, 20 μL of each were pipetted onto clean swabs and
each placed into a tube containing the CERVIS media. The caps were then placed on each of the
tubes and taken outside of the anaerobic hood and placed in the 37 °C incubator. The color
change was then observed every 24 hours, and at 72 hours, it was observed that there was a
significant color change in at least some of the CERVIS tubes. As shown in the table below, at
72 hours, we observed that the 1:101 and 1:103 dilutions had undergone significant color changes.
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Time (hrs)

1:101

1:103

1:105

1:107

1:109

24

48

72

Figure 7: Bacterial Growth Based on Dilution Factor

Due to time constraints, we did not get to complete the rest of this sensitivity procedure as
planned, but we still had developed the overall procedure of how we would complete the rest of
this experiment.

Proposed Experiment
After it had been determined where the color change was occurring within the CERVIS media
tube, we would then take the 1:101 and 1:103 fusobacteria dilutions which were initially pipetted
onto those swabs outside of the hood, and perform DNA miniprep according to Qiagen DNeasy
Miniprep kit (cat. nos. 27104). At that point, we would then perform a qPCR reaction by adding
the normal qPCR components (SYBR Green Master Mix, qPCR grade water) with the forward
and reverse fusobacteria primers (see Appendix B, Section 1 for qPCR experiment methods)
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Therefore, the qPCR machine would amplify the fusobacteria in those dilutions. By plotting the
Ct values generated from the qPCR machine onto the fusobacteria standard curve generated
earlier, it could then be determined how much initial fusobacteria was present in the CERVIS
media where the color change occurred. This would serve as one of the critical numbers that
would be needed in order to generate a percentage to compare to 17% (the percentage of
fusobacteria present on a vaginal swab of a woman with cervical cancer).

4.5.2 Determining Total Bacteria Present on a Vaginal Swab
The second critical number that needed to be obtained was the total amount of bacteria present in
a vaginal swab. To do this, we first needed to collect a vaginal swab.

Obtaining a vaginal swab
Three women from Santa Clara University took gloves and a sterile swab placed in a bag to the
restroom. The swab was removed from the bag using sterilized forceps and the swab was
inserted 1-2 inches into the vagina. After rotating the swab three times inside the vagina, it was
quickly inserted into a dilution blank and the lid was closed. The dilution blank was further taken
to the lab for DNA miniprep.

DNA Miniprep with Tissue Sample
The samples were vortexed for 30 seconds and then prepared according to the protocol for
“cultured cells” in the Qiagen DNeasy Miniprep kit (cat. nos. 27104). The DNA was stored in
the 20 ℃ freezer until ready for use in quantitative PCR (qPCR).

Proposed qPCR experiment with vaginal swab
While we did have the opportunity to obtain vaginal DNA, we did not get the opportunity to
perform a qPCR experiment with this DNA to determine how much total bacteria was present in
a vaginal swab. However, below is the overall procedure for how we would have done so:
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After the vaginal DNA was obtained, it would be added to SYBR Green Master Mix, and the
forward and reverse universal primers. This would amplify all of the DNA found in the vaginal
DNA. After a normal qPCR test was run (see Appendix B, Section 1 for qPCR procedure), the Ct
values given to us from the amplification plot from the qPCR machine would be plotted on the
universal standard curve. This would further tell us how many total bacteria is on a vaginal swab,
which is the second critical number.

4.5.3 Conclusion of Sensitivity Testing
After determining both the amount of initial fusobacteria necessary for a significant color change
to occur in the CERVIS media and the total amount of bacteria in a vaginal swab, a percentage
could then be generated (dividing the fusobacteria by the total bacteria). This number could then
be compared to 17% of fusobacteria that we would expect to find in the vaginal swab of a
woman with cervical cancer. If the percentage was approximately 17%, we could conclude that
the CERVIS media is sensitive enough and therefore, last year’s prototype has feasible
sensitivity.

Unfortunately, because the amounts of fusobacteria and total bacteria were not able to be
determined, we could not generate a percentage. However, we believe that this procedure would
lead us to draw a conclusion of whether the CERVIS media has feasible sensitivity.
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CHAPTER 5: IMPLEMENTATION MODALITIES
5.1 qPCR as Modality
The original purpose of qPCR experiments was to test the feasibility of the CERVIS media
sensitivity. However, we realized that the qPCR procedure could also be used as a clinical
modality to screen women for cervical cancer if a qPCR machine was accessible. Using the
patient’s vaginal swab, the amount of fusobacteria, and the total amount of bacteria could be
determined and plotted on the standard curves to assess the patient for cervical cancer pathology.
This would allow us to generate a percentage, which we could compare to the 17% to assess
whether the woman likely had cervical cancer or not. Therefore, qPCR in itself could be
considered another minimally-invasive implementation modality along with the CERVIS media.

5.2 Comparison of Modalities
We identified two implementation modalities: the CERVIS Media and qPCR experiments. While
both are potentially applicable in a clinical setting, there are several key differences between the
two. The main points are summarized in a table (Table 3) after the following explanations.
First, the CERVIS media is colorimetric and therefore qualitative, while qPCR is a purely
quantitative test. Since the qPCR modality requires specialized equipment, it would be better
suited for communities with pre-existing access to the technology, while the CERVIS media is
ideal for communities without access. There is also a substantial difference between the wait
time for the results of each modality. The CERVIS media relies on the growth of bacteria and
thus requires three to four days for incubation, while the qPCR will determine results much more
rapidly in only a few hours. Both modalities are potentially low enough cost for LMICs if the
qPCR technology is already available.

While the CERVIS media may be more easily implemented in LMICs, preliminary parameter
results suggest the requirement of incubation technology and extended incubation times. These
characteristics may pose significant barriers to clinical implementation in Uganda. A limitation
of the qPCR modality is the requirement of specialized machinery and its accessories, which
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could contribute to an initial high cost. The qPCR cost decreases as more tests are run, which
could vary individual testing costs.

Additionally, both modalities rely on increased concentrations of fusobacteria in the vaginal
microbiome. Fusobacterium colonization of the vagina has also been associated with preterm
birth and a few other uterine infections, so women with these conditions may not be able to
utilize either procedure. Additionally, there remain some cultural limitations of deployment, such
as lack of education surrounding sexual health and the necessity of a community-wide effort to
empower women to care for their own health. Fortunately, we had two public health partners on
our team that worked this year to bridge this gap of education and women’s health empowerment
through the creation of educational brochures. Despite these constraints, we believe that CERVIS
has promising future directions.

Table 2: Summary of the Comparison of Modalities
CERVIS Media
● Qualitative test
● Ideal for communities

Both
● Could be low enough
cost for LMICs

qPCR
● Quantitative test
● Requires highly

without access to

specific lab

qPCR technology

technology

● Results in days

● Results in hours
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CHAPTER 6: SPECIFICITY TESTING
In order for the CERVIS media to be considered functional, it needs to be specific to cervical
cancer. This specificity testing is important because the test can be utilized for detecting a
particular disease, rather than generally detecting a bacteria. A goal for CERVIS this year was to
determine an additional bacterial biomarker that is associated with cervical cancer so that the
procedure is more specific. Unfortunately, an extensive literature review has not yet revealed a
promising candidate to increase specificity, so in this section, we will speculate on what criteria
would make an optimal candidate.

This year, CERVIS focused experiments on the sensitivity of the media to detect fusobacteria.
Sensitivity indicates the true positive of a test, or the ability to correctly identify individuals with
the disease. Another indicator of how accurate a test relies on specificity, the ability to correctly
identify individuals without the disease. Highly sensitive and specific tests are the most accurate,
so both must be considered.

6.1 Selection Criteria for Bacteria
One method of increasing specificity would be to identify a second bacteria to be analyzed
alongside fusobacteria. Currently, there exists no conclusive data on other microbiota implicated
in cervical cancer, but we have developed criteria that this such bacteria would fulfill. In order to
be considered for further analysis, the bacteria must be present or capable of being detected in
cancerous vaginal microbiomes. This is in order to enable the vaginal swab to be effective, i.e.
able to pick up this bacteria when the test is administered. The second criterion is that it be
absent or in significantly low quantities in a non-cancerous vaginal microbiome. This is to
enhance the sensitivity of both qPCR and CERVIS media screening procedures, ensuring that
only cancerous vaginal states are detected. Preliminary parameter testing suggests that incubation
at the typical 37°C for over 72 hours is a requirement for fusobacteria, thus any bacteria that
grow at that temperature or below and for that time or shorter is acceptable. Furthermore,
preliminary tests for aerobic tests indicate the possibility of up to 120 seconds of aerobic
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exposure before no growth is seen in a swab, so the bacteria selected would also need to be able
to withstand aerobic exposure for a reasonable amount of time.

In qPCR, specificity can be increased by focusing on exclusivity and inclusivity. Exclusivity
refers to distinguishing the target strain from similar but genetically distinct non-target strains
through highly specific primers for implementation. As mentioned in Chapter 4, primers for the
exact species, Fusobacterium nucleatum, were used to narrow the scope of detected bacteria. The
second method for increasing PCR specificity is inclusivity, or the range of the qPCR used to
detect a wide range of targets with defined relations such as taxonomic, immunological, and
genetic compositions (Kralik and Ricchi, 2017). Probe-based qPCR assays may also confer an
additional level of specificity, because of its ability to multiplex multiple targets, meaning that
two targets are amplified at once. If a secondary or alternative bacteria were to be identified and
associated with cervical cancer, probe-based qPCR can be used to amplify multiple targets in a
single reaction (Thermofisher, 2020).

An additional qPCR application would be to screen for HPV strains 16 and 18 strains 16 and 18
directly due to their strong correlation to cervical cancer. HPV may be present years prior to
cervical cancer development, while fusobacteria is more strongly correlated with later stages of
cervical cancer. Targeting both in qPCR could be a more accurate indicator of significant and
later stages of cancer development.
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CHAPTER 7: CONCLUSION & FUTURE DIRECTIONS

7.1 CERVIS Media Parameters
For the three parameters—time, temperature, and aerobic exposure—we have only preliminary
data, due to our interrupted time in the lab. However, we were able to determine suggested
parameters for our procedure based on our results. Based on these results we found certain
limitations and future directions. One limitation common to all of our parameter tests was limited
lab time. Time allowing, we would have repeated all parameter experiments and would have run
all of our tests in triplicate.

7.2 Preliminary Results for Incubation Time
We concluded that the optimal time range for incubation at 37 ℃ is between 72 and 98 hours.
While standard incubation times for fusobacteria range from 24-48 hours, when grown in the
CERVIS media, a significant darkening of the media was only observed within the indicated
time range.

7.2.1 Limitations
One of the major limitations of our procedure itself is the extended period of incubation required
to produce a true positive result. Results are not immediately available, which poses an ethical
dilemma because it could potentially cause heightened anxiety while patients wait for results of
the test. This may also require a waiting period for the woman to receive treatment if needed.
This is a shorter duration than a Pap smear, which can take up to 3 weeks to see results, but a
longer wait time than VIA, which can give results almost immediately. Same-day results are
ideal for LMICs, as many women may not have access to a clinic in rural areas and may need to
travel to a city to receive treatment.

In order to continue to improve the procedure, it would be necessary to explore avenues to
decrease fusobacteria growth time. If possible, there would need to be adjustments to the media
in order to promote the growth of bacteria.
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7.3 Preliminary Results for Incubation Temperature
Based on preliminary data testing for incubation at room temperature, 25 ℃, standard incubation
temperature (body temperature), 37 ℃, and the temperature of an available incubator, 30 ℃, we
determined that 37 ℃ is the preferable incubation temperature. However, we acknowledge that
there would need to be additional trials at temperatures between 30 ℃ and 37 ℃ as well as
extended incubation times at lower temperatures such as room temperature to confirm this result.
We also would have conducted testing on the effect of varying temperatures on fusobacteria
growth.

7.3.1 Limitations
A major limitation of the observed incubation temperature preliminary findings is that if there is
limited access to an incubator at 37 ℃, then the procedure may not be able to produce a true
positive result. Average temperatures in Uganda are often lower than 37 ℃, which would make
incubation at room temperature unlikely according to our current findings.

7.4 Preliminary Results for Aerobic Exposure
Based on preliminary data, we concluded that fusobacteria-containing swabs can be exposed to
air for at least two minutes and still produce a true positive result. This is a reasonable collection
time for a vaginal swab, which indicates that this test could be viable once ready for deployment.
Further exploration into the time period between 120 and 300 seconds is required to establish a
true threshold for when fusobacteria is no longer viable.

7.4.1 Limitations
Another limitation of our experimental design was inconsistency in results between duplicate
tests. Due to the variability of the bacterial suspension, there was no way to tell how much
bacteria was contained in the 20 μL of solution that was pipetted onto the swab. In order for
consistent results to be obtained, the tests must be repeated to ensure that each swab has
fusobacteria on it when placed into the media.
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7.5 Sensitivity Results
Time constraints prohibited us from determining whether last year’s prototype has feasible
sensitivity to screen for cervical cancer. However, we were able to develop an absolute standard
curve and an experimental procedure that would allow us to determine the amount of
fusobacteria needed in the CERVIS media for a color change to occur. This amount would have
enabled us to generate a percentage that we could compare to 17%, the amount of expected
fusobacteria present in a vaginal swab of women with cervical cancer. With such results, we
could then conclude whether the CERVIS media was sensitive enough to screen for cervical
cancer.

7.6 Future Directions
Our shortened time in the lab left us with preliminary results of the CERVIS media parameters,
but there are other elements to consider to further define field testing parameters. These include
the effects of varying temperature, humidity, and other related environmental factors. While we
largely focused on sensitivity, determining true negatives by increasing specificity may also play
a part in creating a more accurate prototype and qPCR procedure. This may come in the form of
additional precancerous or cancerous biomarkers, but there are many more to explore. In order to
standardize the color change occurring in the CERVIS media, we believe a color gradient chart
would be beneficial to accompany the media for deployment. Finally, an important future step in
our project would be to find a clinical or industry partner to test both modalities with vaginal
swab samples of women with cervical cancer. Establishing this partnership is essential to assess
the functionality of each procedure.

This year, team CERVIS designed experiments to confirm the feasibility of screening for
cervical cancer using fusobacteria in vaginal samples for LMICs. This procedure is intended to
be sensitive, low-cost, and minimally invasive which we believe could help increase screening in
Uganda. We established two modalities—the colorimetric CERVIS media and qPCR—and both
of these could have future implications. The potential low cost of qPCR creates a market for
low-income or uninsured women in developed countries such as the United States. Furthermore,
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fusobacteria is associated with other types of cancers such as oropharyngeal & colon cancers and
has the potential for screening. These implications indicated that screening for this particular
bacteria has potential beyond the scope of our project.
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CHAPTER 8: ENGINEERING STANDARDS
8.1 Realistic Constraints
Both the qPCR and colorimetric CERVIS media assay procedures are reliant upon the detection
of Fusobacterium nucleatum b acteria in the vagina, t he strain linked to cervical cancer
(Audirac-Chalifour et al., 2016). However, that particular species has also been linked to preterm
birth and intrauterine infection (Diguilio, 2012). Additionally, the presence of sialidase, a
biochemical marker, promotes growth of fusobacterium nucleatum (Agarwal et. al., 2018).
Furthermore, women who test positive for bacterial vaginosis are more likely to be vaginally
colonized by Fusobacterium nucleatum, which may be a cause of the preterm birth (Han et. al.,
2009). Due to these findings, it may be inferred that the upregulation of fusobacteria may occur
in women with bacterial vaginosis or those who have just given birth preterm. Similarly, high
levels of sialidase in addition to fusobacteria, there may be causing upregulation. These disease
states are not indicative of cervical cancer, and therefore we must suggest that women with these
conditions be excluded from screening by our methods.

One of the significant constraints in the deployment of either procedure in Uganda and other
LMICs is the cultural limitation. The lack of education surrounding sexual health, in particular
cervical cancer screening as well as the necessity of a community-wide effort to empower
women to take care of their own health. An additional cultural constraint is the reticence to seek
pelvic examinations, so even in countries with screening in place, women may not seek treatment
until they present with advanced disease (Sankaranarayanan et al., 1998; Juárez-Figueroa et al.,
1998; Safaeian et al., 2007).
8.2 Ethics
Ethical Justification for Project
The primary ethical justification for our project centers on the principle of justice. The principle
of justice states that all humans have inherent dignity in and of themselves, and as such have
fundamental human rights. These rights include access to good healthcare that will allow them to
maintain their health to the highest possible degree. Article 25 of the Universal Declaration of
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Human Rights written and distributed by the United Nations states that each person “has the
right to a standard of living adequate for the health and well-being of himself and his family,
including….medical care and necessary social services” (United Nations, 1948). Therefore,
anyone who does not have an equal opportunity to access medical care must be prioritized.
Additionally, a collaboration between nations with more resources and those with less could lead
to better inter-country relationships, establishing a global community.

Our project focuses specifically on women’s health in Sub-Saharan Africa, namely Uganda.
Women’s health is a globally significant issue but is especially relevant in this region because of
the shortages in equipment and personnel. Our main focus, cervical cancer, is very deadly,
especially in areas with limited access to preventative, screening, and diagnostic measures.
Without access to these measures, the incidence of cervical cancer and the mortality rate of
women in this region of the world will remain high.

Developing a procedure that is minimally invasive, low cost, and can be self-administered has
the potential to benefit the common good by increasing screening rates in Uganda. Limiting the
number of highly invasive procedures such as VIA or the Pap smear will help to minimize
unnecessary procedures and costs respectively.

What Does Our Product Teach Us About the Character of an Engineer?
According to the Biomedical Engineering Society (BMES) code of ethics, biomedical engineers
have certain ethical responsibilities that they must adhere to when working in the field. These
responsibilities extend to us as undergraduate researchers, especially because our procedure is
intended to have clinical applications. These ethical responsibilities can be categorized in three
ways: healthcare obligations, professional obligations, and research obligations.

The healthcare obligations that help to elucidate the ethical focus of our project involve
“consider[ing] the larger consequences of [our] work in regard to cost, availability, and delivery
of healthcare” (BMES Code of Ethics). With the target population of our procedure residing in
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Uganda, it is important to create a procedure that can be readily available, low cost, and easy to
distribute. Working with the Santa Clara University Frugal Innovation Hub and the connections
that we met during the Collaborate 4 Africa event, our team was able to better understand the
needs of the women living in Uganda. The aspects of our prototype that focus on addressing the
obligations include the low cost, easy accessibility (capability to be self-administered), and
small, self-contained design that would allow for ease of distribution.

The professional obligations associated with our project include using our “knowledge, skills,
and abilities to enhance the safety, health, and welfare of the public” (BMES Code of Ethics).
Using the knowledge we have gleaned as undergraduates and with the help of faculty and
industry advisors, we have sought to create a procedure that is safe and acknowledges the needs
of the women in rural Uganda. By conducting experiments to enhance our understanding of
cervical cancer and the prototype created, we have worked towards enhancing the health of the
public.

Finally, the research obligations associated with our project included complying with university
standards and documenting our research carefully. In complying with university safety
guidelines, we completed biology/microbiology general safety training and lab-specific training,
to ensure that our team doesn’t put our own safety or the safety of others in jeopardy.
Additionally, we carefully documented all of our work to ensure that future iterations of the
project are possible and any work that we performed may be easily repeatable.

Ethical Challenges Regarding Safety & Risk
The main ethical challenge regarding the safety of our procedure was the use of anaerobic
bacteria in our experiments. Utilizing this type of pathological bacteria meant that we needed to
make sure that no contamination occurred and that none came into contact with skin, eyes, etc.
To combat this, we followed the safety guidelines dictated by the university as well as national
standards, which included keeping the bacteria inside the lab.
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8.3 Engineering Standards
Besides ethics, our design incorporates economic, social, and health and safety engineering
standards.
Economic
Due to the focus of our project primarily being determining feasibility and assessing preliminary
results of the CERVIS media, we understand that the exact cost is not within the scope of our
project. Because our target population of women resides in Uganda, we would want the cost of
our procedure to be comparable to VIA, which would mean between about $5-20 (Quentin et. al,
2011). Our second modality, the qPCR procedure, relies on a SYBR Green-based assay. We
chose this for its economical feasibility while doing a few preliminary tests on single targets.
However, if this procedure were to be scaled up, probe-based qPCR assays would be the better
option to ensure specificity in addition to sensitivity (Thermofisher, 2020).

Social and Cultural Impact
The primary goal of our project design is to have a significant social and cultural impact.
Because of Uganda’s extremely low rate of cervical cancer screening, it follows that cervical
cancer is the leading cause of cancer-related deaths in Ugandan women. One reason for low
screening is a lack of education surrounding sexual health and the necessity of a
community-wide effort to empower women to take care of their own health. Our two public
health partners have been working to bridge this gap of education and women’s health
empowerment through the design of an educational brochure.

Some factors that inhibit women’s engagement in cervical cancer screening have been identified
as fear of the screening procedure, fear of the outcome, residing in a remote or rural area, limited
resources/health infrastructure, and limited access to screening care (Black, 2019). These point to
immediate ethical concerns of interpersonal communication of women’s health conditions and
strategies for treatment as well as considerations for prototype function; therefore, we intend for
this prototype to be deployed in a healthcare clinic.
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Health and Safety
The most important components of our project are health and safety. Our goal is to improve the
health of women by enabling them to screen for cervical cancer, the fourth most common cancer
in women around the world. However, the majority of the deaths that occur due to cervical
cancer are in LMICs. Many of these deaths could be prevented by screening and early diagnosis.
The main objective of the CERVIS procedure is to provide a way to increase screening through
the development of a sensitive, low-cost, minimally invasive screening procedure that requires
minimal healthcare expertise to administer.
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APPENDIX A: Tables & Figures

Table A: Funding Received
Source of Funding

Amount Received

SCU School of Engineering

$1500

Xilinx Grant

$500

Total Received

$2000

Table B: CERVIS Expenditures
Product

Product Name

Product

Category
Lab
Consumables

Puritan 3306-U Standard
PurFlock Ultra Flocked Tip
Applicators with Polystyrene
Shaft

$13.65

$19.00

$76.12

$82.97

$193.00

$460.00

$91.01

$103.68

$17.91

$39.23

iTaq™ Universal SYBR®
1725120
Green Supermix, 200 x 20 µL
rxns, 2 mL (2 x 1 mL)

$139.00

$173.31

DNeasy Blood & Tissue Kit
(50)

$171.00

$231.23

Nitrogen Gas Tank
0.1-10 microliter pipette tips

Consumables

Tissue kits

Total Cost

Number

Anaerobe Indicator Test for
microbiology

Cell Culture

Unit Cost

3306-U

59886-1PAK-F
-69504

Water, Sterile. WFI Quality.,
Poly Bottle, 500 mL
4.86505.0500

69504
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Fusobacteriarelated items

Fusobacterium nucleatum
subsp. nucleatum Knorr

$61.20
25586

Fuso and universal primers

19084632

Total Expenditures:

$292.65

-

$29.25

-

$1,431.32

Table C: 2019-2020 Academic Timeline for CERVIS
Fall Quarter

Winter Quarter

Spring Quarter

Week 1

● Partnership formed
between BIOE
students and EWH
students

● Additional materials and
primers ordered
● Lab trained to Dr.
Whittal’s lab (for qPCR
access)
● Wrote overview for
sensitivity protocol

● Brainstorming session
for new direction of
CERVIS after all
future lab work is
canceled

Week 2

● First meeting with
engineering team
members and advisor

● Plate Vaginal bacteria
● Performed CFU
experiment with vaginal
samples
● Met with Dr. Park and
agreed to move forward
with qPCR

● Additional Literature
Review on Vaginal
microbiome
● Discuss future
direction with project
advisors

Week 3

● Define goals and
parameters for
CERVIS
● Literature research on
existing diagnostic
tests
● Initial meeting with
Dr. Stephens

● Order materials for
● Meet with advisors to
qPCR
discuss “the story” of
● Meeting with Dr.
our final Senior
Dahlhoff to be trained on
Design Presentation
running a qPCR
experiment in the lab
● Meeting with Dr. Park
on how to create a
Standard Curve on the
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qPCR machine
● Develop overview of
experimental procedure
for sensitivity testing
with qPCR
Week 4

● Initial meeting with
● Trained by Dr. Ruscetti
Dr. Parker, Will, and
in the Anaerobic hood
Lauren
● Brainstorming Session
on constraints and key
questions for CERVIS

● Presentation to Dr.
Parker on first half of
Senior Design
Presentation

Week 5

● Meet with Clarie
Hultquist from last
year’s CERVIS team
to discuss
recommendations on
our future direction
● Literature review on
biomarkers in the
blood, urine, and
menstrual blood
● Senior Design
Funding Proposal
submitted to School of
Engineering

● Took vaginal samples
and purified them using
the DNeasy kit
● Determined
concentration of vaginal
samples using Qubit
● Met with Dr. Park and
Dr. Dahlhoff to discuss
qPCR experimental
design and setup
● Ran qPCR on E. coli
with Universal primer

● Updated presentation
to Dr. Parker

Week 6

● Research other
possible bacteria to
increase specificity of
CERVIS media

● Plated Fusobacteria
● Ran qPCR experiment
with Universal and
Fusobacteria primers on
vaginal bacteria
● Determine color change
of CERVIS media after
adding in Fusobacteria
● CFU experiment with
Fusobacteria

● Presentation to Dr.
Parker and Dr. Asuri
● Submit RD of chapters
3-5 of thesis
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Week 7

● Research other
possible bacteria to
increase specificity of
CERVIS media

● qPCR experiments with
E. coli and Fusobacteria
and Universal and
Fusobacteria primers

● Run through
presentation with
technical and
non-technical
individuals

Week 8

● Safety trained in Dr.
Stephens lab

● Plate additional
Fusobacteria in
anaerobic hood
● qPCR experiments with
E. coli and Fusobacteria
and Universal and
Fusobacteria primers

● Submit recording of
Senior Design
Presentation

Week 9

● Presentation for
Collaborate 4 Africa
● Met with Hiram at
Anaerobic Systems

● Replate Fusobacteria
● Senior Design
● CFU experiment with
Presentation
Fusobacteria
● Meeting with Dr.
Stephens on using a
high-powered
microscope for counting
bacteria
● qPCR experiments with
E. coli, Fusobacteria and
vaginal bacteria using
Universal and
Fusobacteria primers
● Parameter testing with
CERVIS media
(temperature, aerobic
conditions)
● Hemocytometer
counting
● Create Universal and
Fusobacteria standard
curves with fusobacteria
● IEEE Conference
Presentation
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Week
10

● Order materials from
Anaerobe Systems
● Practice streaking
plates with E. coli
● Anaerobicity testing
with E. coli in an
anaerobic pouch,
anaerobic jar, and
aerobic conditions

● Create Universal and
Fusobacteria standard
curves with fusobacteria
● Classes moved to online
platform; labs closed

Table D: Universal Master Mix Experimental Setup qPCR
Reagents

Volume/reaction

SYBR Green Master Mix

5 μL

Universal Forward Primer 0.2 μL
Universal Reverse Primer

0.2 μL

PCR grade water

2.6 μL

Table E: Fusobacteria Master Mix Experimental Setup qPCR
Reagents

Volume/reaction

SYBR Green Master Mix

5 μL

Fusobacteria Forward Primer

0.2 μL

Fusobacteria Reverse Primer

0.2 μL

PCR grade water

2.6 μL

● Final Thesis
Submission
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Table F: No Primer Control (NPC) Experimental Setup qPCR
Reagents

Volume/reaction

SYBR Green Master Mix

5 μL

PCR grade water

3 μL

Table G: Primer Sequences Used in qPCR Experiments
Primer

Primer sequence

Fusobacterium

F: 5’- CAACCATTACTTTAACTCTACCATGTTCA-3’

nucleatum

R: 5’-GTTGACTTTACAGAAGGAGATTATGTAAAAATC-3’

Universal Primer

F: 5' CCTACGGGNGGCWGCAG 3'
R: 5' GACTACHVGGGTATCTA ATCC 3'

Table H: UMM and FMM Total Volumes (Testing Primers)
Reagents

Volume/10 μL

Number of reactions

Total Volume

SYBR Green Master Mix 5 μL

12

60 μL

Forward Primer

0.2 μL

12

2.4 μL

Reverse Primer

0.2 μL

12

2.4 μL

PCR grade water

2.6 μL

12

31.2 μL
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Figure A: qPCR Plate Setup for Testing Primers

Table J: UMM and FMM Total Volumes (Absolute Standard Curve)
Reagents

Volume/10 μL

Number of reactions

Total Volume

SYBR Green Master Mix

5 μL

13

65 μL

Forward Primer

0.2 μL

13

2.6 μL

Reverse Primer

0.2 μL

13

2.6 μL

PCR grade water

2.6 μL

13

33.8 μL
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Figure B: qPCR Plate Setup for Generating an Absolute Standard Curve

Figure C: Amplification Plot for Generating an Absolute Standard Curve
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APPENDIX B: Supplemental Information
Section 1: General qPCR Procedure
1. Preparing dilutions of the bacterial DNA
The bacterial DNA (either fusobacteria or E. coli) was removed from the -20 ℃ freezer, placed
on ice, and given time to defrost. Serial dilutions of the DNA were created in nuclease-free
tubes. These tubes were labeled according to their dilution, which was dependent upon the
particular experiment and type of bacterial DNA. PCR grade water was the diluent and the total
amount of volume for each dilution was 20 μL. Each dilution was mixed by agitation of the tube
(“finger flicking”) and centrifuged for five seconds.

2. Creating the Universal and Fusobacteria Master Mix and NPC
The forward and reverse universal and fusobacteria primers along with the SYBR Green Master
Mix were removed from the -20 ℃ freezer, placed on ice, and given time to defrost. Depending
on the number of reactions that were being performed for the given experiment, a different
amount of the primers, PCR grade water, and SYBR Green Master Mix were combined to form
the Universal Master Mix (UMM), Fusobacteria Master Mix (FMM), and No Primer Control
(NPC). See Table D-F in Appendix A for the amount of each component added per 10 μL
reaction.

The given experiment determined how many reactions were being performed (i.e., how many
wells were going to be used on the qPCR plate). Once the total volume for each of the reagents
was determined (obtained by multiplying volume/reaction with the total number of reactions), all
components for the UMM, FMM, or NPC were combined separately in a labeled 1.5 mL
centrifuge tube. The components were then agitated (“finger flicked”) and centrifuged for three
seconds.

3. Combining the DNA dilutions and Master Mix on a qPCR plate
To set up the qPCR plate, a 0.1 mL 96-well plate was placed on a qPCR specific metal ice block.
The UMM, FMM, NPC, and bacterial DNA dilutions were all placed on ice. Eight μL of either
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NPC (for the control), UMM, or FMM was pipetted into each reaction well according to the
particular experiment. Bacterial DNA or water for control (2 μL) was then added to each reaction
well. Layouts of these experiments can be found in Figures A & B in Appendix A.
Microplate well caps were then sealed onto all the filled wells of the qPCR plate. Once sealed,
the qPCR plate was then centrifuged in a salad spinner and spun for 1 minute. The plate was
examined for bubbles and centrifuged again until no bubbles were observed in the plate. The
plate was loaded into the qPCR machine and began running by pressing “Run Program.” The
plate ran for about 1.5 hours and was subjected to further analysis once completed.

Section 2: Preparing Fusobacteria and Primers for qPCR
Preparations for Growing Fusobacteria
Experiments with fusobacteria were conducted in the anaerobic hood. Before plating, a white to
pink anaerobic indicator was opened inside of the chamber to establish that the environment was
indeed anaerobic. Using a 1 mL needle syringe, dilution media was withdrawn and added to the
fusobacteria pellet to rehydrate the lyophilized fusobacteria cells. The fusobacteria was mixed
with dilution media by pipetting up and down. Once mixed, the entire suspension was withdrawn
and transferred back to the original dilution tube containing 5 to 6 mL of dilution media.

Growing Fusobacteria
Fusobacteria suspension in quantities of 10 μL and 1 μL were pipetted onto blood agar plates and
spread using plastic inoculating loops. These dilutions were each plated three times for a total of
six plates. The plates were then placed in a 33 ℃ incubator inside of the anaerobic chamber
agar-side up and incubated for 72 hours. After that time, 30 small colonies of fusobacteria were
obtained using an inoculating loop and placed in a new tube containing 9 mL of dilution
solution. Two milliliters of this dilution solution was used to create dilutions for determining
color change with the CERVIS media (see Section 3.1-3.3), and the rest was taken outside of the
anaerobic hood.
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DNA Miniprep
The fusobacteria suspension was then placed in a microcentrifuge tube 1 mL at a time and
centrifuged at 7500 rpm for 1 minute. Following centrifugation, the supernatant was poured off
into a waste beaker and an additional 1 mL of the suspension was added. This was repeated for
the remainder of the fusobacteria mixture and the pelleted cells were stored in the 20 ℃ freezer
until DNA miniprep could be completed. DNA miniprep was performed according to the Qiagen
DNeasy Miniprep kit (cat. nos. 27104).

Preparing Primers
To prepare for the quantitative PCR, universal and Fusobacterium nucleatum specific-primers
were first hydrated using the following protocol: primers in given tubes were spun down using
microcentrifuge tubes, then molecular grade water was added at an amount relative to the primer
amount in order to create a 100 µM primer stock. This solution was then allowed to sit at room
temperature for 10 minutes. From the stock solution, a working 10 µM stock was created by
diluting the original solution 1:10 in a sterile microcentrifuge tube.

Section 3: Microscopy
I.

Introduction

There is a need for an alternative quantification method that creates a “known” quantity for
generating an absolute standard curve. Our team chose microscopy (hemocytometry) as the best
secondary quantification method for our qPCR experiments.
II.

Methods

One hundred microliters of the initial fusobacteria dilution were pipetted onto a hemocytometer
slide and placed under a Keyence microscope. From the nine 1mm x 1mm boxes on the
hemocytometer slide, three 1mm x 1mm boxes were randomly chosen as a representative
sample. In each of those three boxes, four 0.25mm x 0.25 mm boxes were randomly chosen
among the sixteen boxes, and pictures were taken of the bacteria. The bacteria were counted and
recorded. The bacteria counts for each of four 0.25mm x 0.25mm boxes were added together and
multiplied by four, as the four boxes represented only one quarter of the total boxes in each 1mm
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x 1mm grid. The sum of all of the three 1mm x 1mm was then calculated and multiplied by
three, as these three boxes represented ⅓ of all the total boxes on the hemocytometer slide.
Because the height of the hemocytometer slide is exactly 0.1mm, the total volume of the
hemocytometer is (0.3mm x 0.3mm x 0.1mm) 0.9 mm3 (or 0.0009 mL). With the total number of
bacteria and the total volume of liquid that bacteria were in, the concentration of the bacteria can
be determined. The counts and sums of each of the boxes can be shown in the table below.
III.

Results

Figure D: Microscopy Diagram

Table K: Bacterial Counts Microscopy
1mm x 1mm Boxes
0.25mm x 0.25 mm Boxes

Box A

Box B

Box C

1

288

263

252

2

225

242

241

3

228

221

276

4

272

235

244

1013

961

1013

1013 x 4 = 5252

961 x 4 = 3844

1013 x 4 = 5252

Sum of 4 boxes
Total estimate of bacteria in
each 1mm x 1mm box
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Sum of boxes A, B, C: 5252 +3844 + 5252 = 14,348 bacteria
Estimate of entire grid: 14,348 x 3 = 43,044 bacteria
Concentration of bacteria: 43,044 bacteria/0.0009 mL = 47,826,667 bacteria/mL
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